Mitigating the risk of cytokine release syndrome in a Phase I trial of CD20/CD3 bispecific antibody mosunetuzumab in NHL: impact of translational system modeling

por Hosseini, Iraj, Gadkar, Kapil, Stefanich, Eric, Li, Chi-Chung, Sun, Liping L., Chu, Yu-Waye, Ramanujan, Saroja
Publicado 2020

Clinical pharmacology of trastuzumab emtansine (T-DM1): an antibody–drug conjugate in development for the treatment of HER2-positive cancer

por Girish, Sandhya, Gupta, Manish, Wang, Bei, Lu, Dan, Krop, Ian E., Vogel, Charles L., Burris III, Howard A., LoRusso, Patricia M., Yi, Joo-Hee, Saad, Ola, Tong, Barbara, Chu, Yu-Waye, Holden, Scott, Joshi, Amita
Publicado 2012